Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C5H9FN2O3 |
| Molecular Weight | 163.1375 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 2 / 2 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
N[C@@H](C[C@@H]([18F])C(N)=O)C(O)=O
InChI
InChIKey=PGEYFCBAWGQSGT-SQEVOQPYSA-N
InChI=1S/C5H9FN2O3/c6-2(4(8)9)1-3(7)5(10)11/h2-3H,1,7H2,(H2,8,9)(H,10,11)/t2-,3+/m1/s1/i6-1
| Molecular Formula | C5H9FN2O3 |
| Molecular Weight | 163.1375 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 2 / 2 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
Approval Year
| Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 08:23:35 UTC 2023
by
admin
on
Sat Dec 16 08:23:35 UTC 2023
|
| Record UNII |
XE87369YJP
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
50898367
Created by
admin on Sat Dec 16 08:23:36 UTC 2023 , Edited by admin on Sat Dec 16 08:23:36 UTC 2023
|
PRIMARY | |||
|
1262523-92-1
Created by
admin on Sat Dec 16 08:23:36 UTC 2023 , Edited by admin on Sat Dec 16 08:23:36 UTC 2023
|
PRIMARY | |||
|
XE87369YJP
Created by
admin on Sat Dec 16 08:23:36 UTC 2023 , Edited by admin on Sat Dec 16 08:23:36 UTC 2023
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
TRANSPORTER -> SUBSTRATE |
|
||
|
TARGET->RADIOLIGAND |
HIgher expression in tumors
|
||
|
NON-LABELED -> LABELED |
|
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
ACTIVE MOIETY |
Official Title: A Phase I Study: PET Imaging of Cancer Patients Using (18F) 4-L-Fluoroglutamine (2S,4R)
Purpose: This is a Phase I study. This study is the first time that a new experimental drug called 18FFluoroglutamine, or F-Glutamine, is being used in people. F-Glutamine is a drug designed to be used with PET scanners that can 'see' where F-Glutamine goes in the body, after its injected. PET scanners are one of the kinds of scanners you normally find in a hospital radiology department. The researchers have found that tumors in animals absorb F-Glutamine. The researchers believe that scans with F-Glutamine might be able to find tumors in patients.
This first in-human study is being done to see how long F-Glutamine lasts in the blood, when it is given to people in tiny amounts by an injection, and to see where F-Glutamine goes in the body. If the results of this trial are good, then the study doctors plan to use F-Glutamine in another trial to see if scans with F-Glutamine are better for finding tumors compared to the standard types of scans that doctors use.
|
||
|
ACTIVE MOIETY |
RESULTS: In vitro studies showed that both transformed 9L and SF188 tumor cells displayed a high rate of glutamine uptake (maximum uptake, 16% dose/100 .MU.g of protein). The cell uptake of (18)F-(2S,4R)4-fluoroglutamine by SF188 cells is comparable to that of (3)H-L-glutamine but higher than that of (18)F-FDG. The tumor cell uptake can be selectively blocked. Biodistribution and PET studies showed that (18)F-(2S,4R)4-fluoroglutamine localized in tumors with a higher uptake than in surrounding muscle and liver tissues. Data suggest that certain tumor cells may use glutamine for energy production.
CONCLUSION: The results support that (18)F-(2S,4R)4-fluoroglutamine is selectively taken up and trapped by tumor cells. It may be useful as a novel metabolic tracer for tumor imaging.
|
